Prosecutors allege providers were allowed to retain 30 percent to 40 percent of successful federal reimbursements through arrangements described as discounts, creating profits that authorities contend violated federal kickback laws
WASHINGTON, DC — Federal prosecutors accuse Michael McMillan of offering physicians, podiatrists, and other medical providers an unusually direct financial proposition: use skin-substitute products supplied through his companies, obtain government reimbursement, and keep a guaranteed share of the resulting payment.
The indictment alleges that participating providers retained approximately 30 percent to 40 percent of reimbursements paid by Medicare, TRICARE, and CHAMPVA, while companies controlled by McMillan collected the remaining portion only after government programs approved the underlying wound-care claims.
Authorities describe those retained amounts as illegal kickbacks disguised through the familiar commercial language of rebates and discounts, rather than legitimate price reductions independently established before treatment and unrelated to the value or success of federally reimbursed business.
McMillan has not been convicted; every accusation remains unproven, and the United States must establish his knowing and willful participation in each charged offense beyond a reasonable doubt through admissible evidence tested before an impartial court.
A Reimbursement Share Presented as a Rebate
According to the federal indictment against Michael McMillan, Protectus LLC and related entities allegedly supplied expensive skin substitutes without requiring medical providers to pay the ordinary purchase price before applying those products to patients and submitting claims.
If a government program denied reimbursement, prosecutors say the provider generally owed Protectus nothing for the associated product, eliminating the inventory loss that a conventional purchaser might otherwise absorb when an insurer rejects payment after treatment.
When reimbursement arrived, however, Protectus allegedly invoiced the provider for approximately 60 percent to 70 percent of the government payment, leaving the medical practice with the remaining 30 percent to 40 percent as a predictable financial benefit.
That retained portion allegedly generated thousands of dollars for each successful claim, creating what the Justice Department characterizes as a guaranteed profit rather than an ordinary discount whose amount and commercial risk would exist independently of government reimbursement.
The distinction between those descriptions will become central because federal kickback law examines the purpose and economic substance of remuneration, permitting prosecutors to look beyond contractual labels when deciding whether something valuable was offered to influence federally funded ordering decisions.
Why the Guarantee Mattered
Ordinary product purchasing usually requires a medical practice to evaluate clinical usefulness, acquisition cost, inventory needs, payment timing, and denial risk before committing capital, even when wholesalers extend credit or manufacturers offer properly documented commercial discounts.
The alleged Protectus model changed that risk calculation by requiring no upfront payment, imposing no product charge following a denial, providing billing assistance, and preserving a substantial margin whenever a federal program paid the claim.
From the government’s perspective, those combined features made product selection financially compelling because a participating provider could avoid most downside exposure while receiving a large percentage of public reimbursement after a successful submission.
McMillan’s defense may argue that delayed invoicing, contingent credit, replacement protection, risk sharing, or negotiated pricing can serve legitimate business purposes, particularly within a complicated market where coverage decisions and collection timelines remain uncertain.
Prosecutors must therefore prove more than an attractive arrangement, demonstrating that the guaranteed margin was knowingly and willfully offered or paid to induce federally reimbursable orders and that related claims incorporated materially deceptive information.
The March 2024 Pitch Described by Prosecutors
The indictment recounts a March 2024 meeting during which McMillan allegedly told an unidentified Texas podiatrist that Protectus provided medical practices with an average rebate of 35 percent when they used skin-substitute products offered through his business network.
Prosecutors say McMillan illustrated the opportunity by explaining that a provider collecting $180,000 from Medicare during one month could retain 35 percent, or approximately $63,000, under the proposed financial arrangement with Protectus.
That example may matter because it allegedly framed the provider’s expected return as a percentage of Medicare collections, allowing prosecutors to argue that government payment volume, rather than a conventional wholesale price, determined the promised economic benefit.
During the same discussion, McMillan allegedly said he personally reviewed every Medicare claim to ensure that Protectus products were billed at a higher price than providers actually paid, an assertion the defense will be entitled to challenge through complete context and testimony.
Protectus subsequently supplied the podiatrist with 12 skin-substitute products at no upfront cost during March or April 2024, according to prosecutors, moving the alleged presentation from a hypothetical earnings illustration into a documented commercial relationship.
One Paid Claim and One Denied Claim
The indictment says the podiatrist later informed a Protectus employee that Medicare had paid $9,024 for one claim while denying another, creating a compact example of how the alleged reimbursement-contingent arrangement operated after claims adjudication.
The employee allegedly explained that Protectus would invoice for the paid claim while helping the practice address the denial, meaning the provider’s product obligation depended on whether Medicare had released money rather than simply whether inventory had been delivered.
Protectus then allegedly invoiced the provider $5,865.60, representing exactly 65 percent of the reported $9,024 reimbursement, while the provider retained the remaining 35 percent, or $3,158.40, under the arrangement prosecutors described.
For investigators, that arithmetic supplies transaction-level evidence connecting the promised rebate to a specific Medicare payment, because the invoice allegedly emerged only after reimbursement and matched the percentage McMillan had discussed with the provider.
The defense can nevertheless examine whether the invoice represented a legitimate net purchase price, whether the denied product remained returnable or otherwise chargeable, and whether additional contract terms materially alter the government’s description of the transaction.
Discount Language and Federal Kickback Law
The federal Anti-Kickback Statute does not prohibit every discount, rebate, credit, warranty, replacement policy, or sales commission involving a product reimbursable by Medicare or another government program, since lawful health-care commerce routinely includes carefully structured price concessions.
Criminal exposure arises when a person knowingly and willfully offers or pays remuneration to induce or reward the purchase, ordering, recommendation, or arrangement of an item or service for which a federal health-care program may provide payment.
Discount protections generally depend upon the parties, transaction structure, documentation, and required disclosures, making the complete economic arrangement more important than whether an agreement repeatedly uses reassuring terms such as rebate, discount, wholesale price, or account credit.
An arrangement falling outside a regulatory safe harbor is not automatically criminal, because safe harbors protect qualifying conduct while prosecutors still bear the burden of proving unlawful intent and every other required statutory element.
The McMillan case will therefore test whether the provider margins represented genuine purchase-price reductions or remuneration calculated to reward federal program business, a question likely to turn upon communications, contracts, invoices, claim records, payment timing, and witness credibility.
Acquisition Cost and the Claim Form
Prosecutors also allege that challenged claims misrepresented providers’ true acquisition costs, connecting the rebate theory with the information supplied to government programs when medical practices requested federal payment for those expensive skin-substitute products.
The indictment focuses upon pricing information entered in Box 19 of certain Medicare claims, asserting that the disclosed figure should have reflected the provider’s total invoice price after applicable discounts, rebates, refunds, and other adjustments.
From the government’s perspective, a provider that reported a higher acquisition figure while privately expecting to pay only 60 percent to 70 percent of reimbursement gave Medicare a materially incomplete picture of the transaction’s actual economics.
Protectus employees allegedly submitted claims for participating providers or assisted their billing, giving the company access to reimbursement details and enabling it to calculate the percentage invoices, retained provider margins, and representative commissions described throughout the charging document.
In the Texas podiatrist example, a Protectus employee allegedly noticed that Box 19 information was missing and directed the provider to resubmit the claim using pricing drawn from a company spreadsheet, an episode prosecutors may cite as evidence of operational involvement.
Materiality and Responsibility Remain Contested
The legal significance of Box 19 will depend upon the governing instructions, the accuracy of the reported amount, the complete provider obligation, the roles played by independent billers, and whether any challenged representation was material to the program’s payment decision.
McMillan may contend that providers controlled their own claims, that experienced billing personnel interpreted complex guidance in good faith, or that invoice amounts represented enforceable prices despite later credits, adjustments, denials, refunds, or disputed collections.
Prosecutors, conversely, may argue that the reimbursement-based percentage existed from the outset and that presenting a larger acquisition amount concealed the provider profit that allegedly induced selection of Protectus products.
Because aggregate reimbursement figures cannot independently prove falsity on every claim, the parties may contest sampling methods, patient records, product quantities, invoice calculations, disclosure requirements, and each participant’s knowledge associated with selected submissions.
That claim-specific inquiry matters because genuine product delivery and medically valuable treatment do not necessarily defeat a fraud theory involving kickbacks or material misrepresentations, while a profitable or expensive claim alone cannot establish deliberate criminal deception.
Invoices Allegedly Recorded the Percentage Split
The indictment describes an October 2022 invoice involving an unidentified Utah podiatrist who allegedly collected $53,625.60, retained $16,087.68, and owed Protectus $37,537.92, amounts corresponding precisely to a 30 percent provider share and 70 percent company share.
Another allegation concerns a July 2023 invoice sent to an Arlington, Texas, physician whose employee reportedly complained that the document reflected a 35 percent provider profit although a newer contract allegedly promised the practice a 40 percent share.
McMillan allegedly directed that the calculation be corrected, an exchange prosecutors may portray as direct knowledge that provider compensation moved according to an agreed percentage of collected reimbursement rather than a fixed product price established before billing.
The defense may answer that percentage-based net pricing can be recorded openly and adjusted through ordinary accounting, particularly when the invoices themselves preserved the transactions instead of concealing payments through cash, false vendors, or undisclosed personal transfers.
A December 2023 email described in the indictment involved another provider requesting a refund after returning claim payments to Medicare for rebilling through a different company, and Protectus allegedly processed the refund through its financial system.
Sales Representatives and a Second Contingency
McMillan allegedly employed representatives to recruit physicians, podiatrists, nurse practitioners, and other providers, instructing them to explain the profit opportunity and expand the reimbursement-based model across medical practices in several states.
The representatives were allegedly paid only after recruited providers received government reimbursement and transferred Protectus its percentage, creating another contingent payment layer tied to the success and value of federally funded skin-substitute claims.
Prosecutors estimate that Protectus paid representatives about $27 million, characterizing those commissions as additional kickbacks, although lawful sales compensation exists and the government must prove these payments met the statutory requirements for criminal liability.
One communication described by prosecutors involved a representative disputing a commission report that omitted $6,446.55, while a company employee allegedly explained that commission became payable only after the medical office confirmed insurance had paid the underlying claim.
The government’s financial narrative therefore follows a three-stage chain: federal programs paid medical providers, providers retained the alleged rebate and paid Protectus, and Protectus compensated representatives according to collections generated by recruited practices.
The Aggregate Money Alleged by the Government
Federal programs allegedly paid approximately $268 million on skin-substitute claims connected to the scheme, with participating providers retaining about $94 million and McMillan’s Protectus companies receiving approximately $174 million, according to the government’s calculations.
Those figures should not be added together as separate losses because the $94 million provider share and $174 million Protectus share describe the alleged allocation of the broader $268 million reimbursement stream, subject to proof and possible dispute.
The $27 million allegedly paid to sales representatives likewise represents money distributed from company receipts rather than an additional $27 million automatically added to the claimed government payments, an important distinction when evaluating headline totals.
Authorities further reported seizing assets valued at approximately $35 million, while the indictment seeks forfeiture of property allegedly traceable to fraud, kickback activity, or specified monetary transactions if prosecutors ultimately obtain the necessary convictions and findings.
Pretrial seizure preserves disputed assets while litigation proceeds, but it neither proves criminal origin nor guarantees permanent forfeiture, leaving McMillan and qualifying third parties able to challenge ownership, tracing, valuation, probable cause, and substitute-asset theories.
Luxury Purchases and Transaction Counts
The indictment alleges that McMillan used proceeds to acquire houses, condominiums, luxury vehicles, and a private aircraft, while seven monetary-transaction counts identify particular transfers involving high-value property that prosecutors contend was purchased with criminally derived funds.
Those counts concern transactions allegedly connected to real estate, a Lamborghini, a Cadillac Escalade, and a Cessna Citation aircraft, giving the government discrete transfers to trace rather than requiring every business expenditure to be characterized identically.
Luxury evidence can make a prosecution vivid for jurors, yet wealth and expensive purchases do not prove fraud by themselves, and the defense may seek to exclude inflammatory details or demonstrate that particular assets came from legitimate, commingled, or independently sourced funds.
For each financial count, prosecutors must establish the statutory amount, McMillan’s required knowledge, the qualifying criminal source of the property, and the relationship between the identified transaction and proceeds of the alleged underlying offenses.
Three Government Programs Financed the Claims
The challenged reimbursements allegedly came from Medicare, TRICARE, and CHAMPVA, placing older or disabled beneficiaries, military families, and qualifying dependents, survivors, or caregivers connected to veterans within the financial systems at issue.
Skin substitutes can provide legitimate clinical value for carefully selected chronic wounds, particularly when practitioners document medical necessity, wound dimensions, prior conservative treatment, product application, discarded material, patient response, and appropriate follow-up care.
The prosecution does not become valid merely because a product was costly, a provider earned money, or a billing pattern appeared unusual, since legitimate specialization and successful treatment can generate large reimbursements without proving unlawful intent.
Nevertheless, reimbursement structures can create powerful incentives when providers obtain products without upfront cost, avoid liability after denial, and retain thousands of dollars following approval, making independent clinical judgment and transparent pricing essential safeguards for patients and taxpayers.
Nine Counts in the Federal Indictment
The nine-count case includes a conspiracy to commit health-care fraud, a conspiracy to defraud the United States and pay unlawful health-care kickbacks, and seven allegations of monetary transactions involving property derived from specified criminal activity.
The health-care fraud conspiracy requires proof of a knowing agreement to execute or attempt a fraudulent scheme involving a health-care benefit program, while the defense can challenge whether McMillan intentionally joined any agreement containing materially deceptive objectives.
The kickback-related conspiracy places purpose at the center of the case, requiring prosecutors to show that challenged rebates, discounts, commissions, or other remuneration were knowingly connected to inducing or rewarding federally reimbursable purchases and orders.
The remaining counts require transaction-specific tracing beyond the broader reimbursement narrative, meaning prosecutors must connect identified transfers exceeding the statutory threshold to qualifying criminal proceeds while proving the knowledge element applicable under federal law.
Potential imprisonment, restitution, fines, and forfeiture can be substantial after conviction, although statutory maximums do not predict an actual sentence, which depends on proven conduct, guidelines calculations, criminal history, role, loss, acceptance, and judicial findings.
The 2026 National Health Care Fraud Takedown
McMillan’s prosecution emerged through the Justice Department’s 2026 National Health Care Fraud Takedown, a coordinated initiative that announced charges against 455 defendants across 56 federal districts in alleged schemes collectively involving more than $6.5 billion in false claims.
The national operation included 90 doctors and other licensed professionals, reached 45 states and territories, and combined criminal cases with civil settlements, exclusions, payment suspensions, billing revocations, controlled-substance actions, and extensive asset seizures.
In North Texas, authorities announced seven cases involving 13 defendants and more than $365 million in alleged fraudulent billing, making the McMillan matter the region’s largest disclosed prosecution by the government-payment figure associated with its allegations.
Independent NBC 5 Dallas-Fort Worth coverage of the North Texas enforcement action described cases involving wound-care products, hospice services, laboratory testing, brain-related procedures, COVID-19 kits, durable medical equipment, elderly beneficiaries, and military families.
Federal officials credited investigators from the Federal Bureau of Investigation, the Department of Health and Human Services Inspector General, the Defense Criminal Investigative Service, and the Department of Veterans Affairs Inspector General with developing McMillan’s case.
Analytics Can Reveal a Guaranteed Margin
Modern claims analysis can identify providers whose skin-substitute billing rises sharply after contact with a distributor, products generating exceptional reimbursement, repeated percentage margins, denial-dependent invoices, and representative commissions that move with government collections.
Investigators can compare claim dates, product codes, square centimeters, beneficiary histories, payments, invoice percentages, bank deposits, representative reports, and communications to create a chronological map that may reveal whether a commercial arrangement operated as prosecutors allege.
Statistical abnormality remains an investigative lead rather than proof of guilt, because specialized patient populations, new service lines, regional referrals, genuine clinical success, or rapid lawful expansion can produce dramatic data without establishing corrupt intent.
The decisive question will be whether analytics align with contracts, spreadsheets, invoices, emails, witness testimony, and claim instructions demonstrating a deliberate reimbursement-sharing system, or whether complete records support commercially legitimate explanations for the same patterns.
Compliance Lessons for Providers and Distributors
Distributors should set prices based on documented commercial factors, not simply by dividing future government reimbursement, especially when proposed terms eliminate provider downside while promising unusually large margins after federal programs approve claims.
Medical practices should independently verify clinical necessity, coverage criteria, acquisition cost, rebate treatment, product quantity, claim accuracy, and disclosure requirements rather than assuming distributor billing assistance shifts legal responsibility away from the enrolled provider.
Sales compensation requires specialized review whenever representatives recruit practices serving federal beneficiaries, because commissions based on the value or volume of reimbursed orders can create serious kickback exposure, even when described as conventional marketing or business-development payments.
Manufacturers should also monitor downstream distribution practices, since aggressive reimbursement promises and poorly supervised sales channels can expose products and brands to investigations even when the charging document does not accuse any identified manufacturer of wrongdoing.
Organizations should preserve contracts, price schedules, rebate calculations, invoices, denial records, spreadsheets, claim-support messages, clinical documentation, shipment records, commission reports, and compliance advice, because contemporaneous evidence frequently determines whether unusual conduct appears lawful or intentionally deceptive.
Responding to Public Allegations Lawfully
A major indictment creates immediate reputational consequences for executives, companies, employees, medical providers, and commercial partners, often producing durable search results before discovery, motions, expert analysis, witness examinations, negotiations, or trial establish a complete evidentiary record.
Amicus International Consulting publishes material concerning lawful cross-border planning, identity integrity, due diligence, and reputational exposure, while distinguishing legitimate privacy protection from concealment intended to obstruct regulators, investigators, courts, creditors, or lawful reporting obligations.
Its crisis public-relations resources emphasize early assessment and disciplined communication, principles that matter most when public statements must remain accurate, coordinated with qualified counsel, and clearly separated from witness influence, evidence destruction, retaliation, or obstruction.
Any person or organization confronting federal scrutiny should preserve relevant records, avoid speculative public claims, correct demonstrable factual errors carefully, and ensure that communications distinguish unresolved allegations from adjudicated findings without promising outcomes that available evidence cannot support.
Reputation management cannot erase a legitimate prosecution or substitute for legal defense, but accurate timelines, documented corrections, consistent spokesperson procedures, and transparent updates can help prevent avoidable misinformation from compounding the damage created by unresolved accusations.
What Prosecutors Must Prove
The government must prove that McMillan knowingly and willfully joined the alleged conspiracies, understood the unlawful objectives, and participated in conduct designed to produce materially false claims or prohibited remuneration connected to federal health-care program business.
For the kickback theory, prosecutors must demonstrate that at least one purpose of the challenged provider benefits or representative payments was to induce or reward qualifying orders, rather than merely showing that a discount existed alongside profitable government reimbursement.
For the fraud theory, prosecutors must connect the payment arrangements with material deception, including any inaccurate acquisition-cost representation, while addressing who prepared, reviewed, submitted, and controlled the claims selected as evidence of the alleged scheme.
For the monetary-transaction counts, the government must trace specified property into qualifying criminal proceeds and prove the necessary knowledge, a task that can become complicated when businesses combine allegedly unlawful receipts with revenue from legitimate sales and services.
McMillan’s attorneys may challenge witness credibility, claim sampling, regulatory guidance, search and seizure procedures, expert methodology, loss calculations, provider independence, contract interpretation, safe-harbor analysis, and the government’s tracing of particular assets or transfers.
The Defense Questions Behind the Rebate Label
The defense may argue that the challenged margins were openly documented commercial discounts, that providers made independent clinical decisions, and that reimbursement-contingent terms allocated legitimate collection risk within a volatile and heavily regulated wound-care market.
Attorneys may also examine whether Protectus relied upon compliance professionals, whether government instructions gave fair notice about the disputed acquisition-cost reporting, and whether prosecutors have presented selected messages or invoices without commercial context favorable to McMillan.
Cooperating providers, representatives, employees, or billing specialists could become important witnesses, but jurors would need to assess their consistency, documentary support, financial exposure, immunity arrangements, plea negotiations, personal interests, and reasons for describing the transactions as they do.
None of those possible defenses guarantees dismissal or acquittal, just as the indictment’s large numbers and precise calculations do not guarantee conviction, because the outcome will depend upon evidence, judicial rulings, negotiations, and potentially a jury’s deliberations.
What Happens Next
The prosecution will proceed through arraignment, discovery, pretrial motions, expert review, asset litigation, and possible negotiations, with Assistant United States Attorneys Marty Basu and Chad Meacham publicly identified as the prosecutors handling the Northern District of Texas case.
Likely disputes may involve billing instructions, acquisition-price disclosure, claim sampling, provider autonomy, commission calculations, discount protections, warrant evidence, venue, forfeiture tracing, loss methodology, and the admissibility of communications or lifestyle evidence offered to establish intent.
No reliable public timetable can predict resolution of a document-intensive case spanning nearly seven years, multiple companies, numerous providers, several states, three government programs, extensive claims data, valuable seized assets, and specialized reimbursement questions.
The central accusation remains straightforward despite that complexity: prosecutors say McMillan transformed government reimbursements into a promised provider profit, then used the language of rebates and discounts to make an alleged kickback arrangement appear commercially ordinary.
The broader compliance warning is equally direct: a payment term will be judged by its real purpose, disclosure, timing, and economic effect rather than the reassuring label placed on a contract, invoice, spreadsheet, commission report, or sales presentation.
Most importantly, Michael McMillan remains presumed innocent; all accusations concerning Protectus and its financial arrangements remain allegations, and criminal responsibility can arise only if the government satisfies its constitutional burden through a valid guilty plea or proof beyond a reasonable doubt.
